Free Trial
→ Please open before June 12! (From InvestPub) (Ad)tc pixel
NASDAQ:IVVD

Invivyd Q2 2025 Earnings Report

Invivyd logo
$0.77 -0.04 (-5.23%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$0.78 +0.01 (+0.78%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Invivyd EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Invivyd Revenue Results

Actual Revenue
$11.79 million
Expected Revenue
$23.16 million
Beat/Miss
Missed by -$11.38 million
YoY Revenue Growth
N/A

Invivyd Announcement Details

Quarter
Q2 2025
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Invivyd's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Slide Deck

Invivyd's Q2 2025 Slide DeckFull Screen Slide Deck
Powered by Quartr

Earnings Documents

Invivyd's Q2 2025 Press ReleasePress Release
(8-K)
Invivyd's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Invivyd Earnings Headlines

Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode
June 12 at 1:26 AM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/invivyd-inc-ivvd-reports-clinical-progress-stock-expected-to-explode-1779788/
Invivyd doses first participants in Phase 3 COVID-19 trial
June 9, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1093672?snapi
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
June 14 at 1:00 AM  |  Reagan Gold Group (Ad)
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to ...
June 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invivyd-announces-first-participants-dosed-in-liberty-a-phase-3-clinical-trial-to-evaluate-the-safety-and-tolerability-of-vyd2311-antibody-versus-mrna-covid-vaccine-and-to-characterize-the-safety-1036234991
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308710/0/en/invivyd-announces-first-participants-dosed-in-liberty-a-phase-3-clinical-trial-to-evaluate-the-safety-and-tolerability-of-vyd2311-antibody-versus-mrna-covid-vaccine-and-to-characte.html
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305923/0/en/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

View Invivyd Profile
Earnings Tools